Suven Life Sciences Limited (SUVEN) completes patient enrollment in global Phase-3 study of Masupirdine for agitation associated with Alzheimer’s Dementia.
Suven Life Sciences Limited (SUVEN) to present scientific posters at AAIC-2026, including updates on Masupirdine and Usmarapride.
Suven Life Sciences Limited (SUVEN) to showcase its CNS clinical candidates and partnering strategies at BIO International Convention 2026 in San Diego.
Suven Life Sciences Limited (SUVEN) shares positive topline results from Phase-2b trial of Ropanicant for Major Depressive Disorder.
Suven Life Sciences Limited (NSE: SUVEN) successfully completes Phase-1 study for SUVN-I6107, advancing to Phase-2.
Suven Life Sciences Limited (SUVEN) announces three poster presentations on Samelisant at SLEEP-2026 Annual Meeting in Baltimore, showcasing clinical advance.
Suven Life Sciences Limited (SUVEN) announces positive DSMB safety review and interim analysis from ongoing global Phase 3 study of Masupirdine in Alzheimer'.
Suven Life Sciences Limited reaches 76% enrollment in its Global Phase 3 Masupirdine trial for Alzheimer’s agitation.